Advertisement
UK markets close in 3 hours 50 minutes
  • FTSE 100

    8,119.56
    +40.70 (+0.50%)
     
  • FTSE 250

    19,814.23
    +212.25 (+1.08%)
     
  • AIM

    755.43
    +2.31 (+0.31%)
     
  • GBP/EUR

    1.1670
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.2517
    +0.0006 (+0.05%)
     
  • Bitcoin GBP

    51,250.90
    +294.48 (+0.58%)
     
  • CMC Crypto 200

    1,386.31
    -10.22 (-0.73%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.14
    +0.57 (+0.68%)
     
  • GOLD FUTURES

    2,358.10
    +15.60 (+0.67%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,059.65
    +142.37 (+0.79%)
     
  • CAC 40

    8,045.79
    +29.14 (+0.36%)
     

Why Has Valeant Stock Fallen in June?

Why Has Valeant Stock Fallen in June?

Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.